Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)
Status:
Withdrawn
Trial end date:
2019-03-12
Target enrollment:
Participant gender:
Summary
Non-randomized phase I/II, open-labeled clinical study, 1-arm, multicenter, of docetaxel (T),
cisplatin (P), 5-fluorouracil (F) and pembrolizumab every 21 days for 3 cycles followed by
radiotherapy (RT) combined with carboplatin in untreated unresectable locally-advanced Head
and Neck Squamous Cell Carcinoma (HNSCC).
The TPF and pembrolizumab combination will be called TP²F.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Centre Antoine Lacassagne
Collaborators:
GERCOR - Multidisciplinary Oncology Cooperative Group GORTEC Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)